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Abstract: Aging is associated with weakening of the circadian system. The circadian 
amplitude of most physiological variables is reduced, while the circadian phase becomes 
more labile and tends to occur earlier with advancing age. As the incidence of falls in older 
persons could follow circadian variations, a better understanding of conditions in which falls 
occur can lead to the implementation of countermeasures (such as adjusting the scheduling of 
hospital staff, or changing the timing of anti-hypertensive medication if falls are related to 
undesirable circadian patterns of blood pressure and/or heart rate). This includes knowing the 
times of the day, days of the week, and times of the year when falls are more likely to occur 
at home or in the hospital. Additionally, the links between aging processes and factors 
associated with an increased risk of developing autonomic dysfunction are well established. 
A strong association between heart rate variability indexes and aging has been shown. 
Circadian rhythms of autonomous nervous system activity may play important role for 
maintenance of orthostatic tolerance. Whether one is concerned with disease prediction 
and prevention or maintenance of healthy aging, the study of circadian rhythms and the 
broader time structure underlying physiopathology is helpful in terms of screening, early 
diagnosis and prognosis, as well as the timely institution of prophylactic and/or palliative/ 
curative treatment. Timing the administration of such treatment as a function of circadian 
(and other) rhythms also could lead to reduction of falls in older persons. Finally, 
a prominent circadian rhythm characterizes melatonin, which peaks during the night. The 
circadian amplitude of melatonin decreases as a function of age, raising the questions 
whether such a decrease in the circadian amplitude of melatonin relates to a higher risk of 
falls and, if so, whether melatonin supplementation may be an effective countermeasure. This 
narrative review assesses the relationships between fall risk and the potential role circadian 
rhythms and melatonin play in mitigating this risk. We aim to provide healthcare workers 
adequate information about fall risk in older persons, including the potential role of the 
circadian rhythms and/or melatonin, as well as to lay foundations for future fall prevention 
interventional studies. 
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Introduction
Population ageing has become a global phenomenon. In Europe, 13% of the popula-
tion is aged 65 or more but by 2030, it is expected to almost double to 24%.1 This 
means that the average life expectancy is increasing – largely attributed to the 
development of medical and technological advances – but so are the challenges in 
geriatric care such as medical aspects of care, rehabilitation, nursing, psychology, 
sociology, pharmacy, social aspects, amongst others. According to epidemiological 
data, about 28–35% of people aged 65 or more fall each year and in individuals over 
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70 years of age, the numbers increase to 32–42%.2 This 
indicates that falls in older people must be addressed by 
health-care professionals both in acute and chronic care 
settings.
Falls are considered alarming adverse events due to 
their consequences such as lacerations, bruises, loss of 
function, hip and/or skull fractures or even death.3–6 In 
addition, World Health Organization, WHO (2018) classi-
fied falls as the second highest cause of accidental injuries 
in older persons, and highlighted that programs to avoid 
falls and research in underlying causes of falls should be 
prioritized.7 Falls are adverse events that affect older peo-
ple not only physically but also psychologically and 
socially, impacting on their overall quality of life.5,6 
Consequently, falls and falls-related injuries are common 
problems of Public Health as they are associated with high 
morbidity and mortality in older persons. Besides these 
aspects, falls and fall-related injuries increase costs in 
residential homes, nursing homes, public health services, 
hospitals and to older individuals that have no health 
insurance. Therefore, it is relevant to contribute for patient 
safety by preventing falls in old people.
The etiology of falls is multifactorial and could be 
attributed to the following types of causes: intrinsic (due 
mainly to medical conditions) and extrinsic (largely arising 
due to environmental factors). Intrinsic factors are related 
to physical and psychological state of the person (eg, lack 
of vision and/or hearing, reaction time, musculoskeletal 
disorders, vestibular, proprioceptive and musculoskeletal 
disorders, gait, prolonged sedentary state, among others); 
to diseases (eg, cardiovascular, neurologic, osteoarticular, 
genitourinary, among others); and to drugs (eg, those that 
lead to diminishing of motor functions, dizziness, hypo-
tension, weakness, confusion and bed confinement). 
Extrinsic factors are related mainly to environmental situa-
tions (eg, inadequate lighting, presence of obstacles, slip-
pery surfaces, absence of handrails, among others).8 In 
addition, Montero-Odasso (2018) highlights the impor-
tance of cognitive impairments such as lack of attention 
that compromises postural and gait stability and executive 
functions such as impairment of attention, inhibitory con-
trol, working memory and cognitive flexibility thus lead-
ing to falls.9 All these aspects must also take into 
consideration that older adults with falls exhibit reduced 
mobility and become more bed-confined due to further 
functional impairment associated with bedrest per se and 
fear of further falls. Specifically, fear of falling might lead 
to increased likelihood of falling as well as activity 
limitation or avoidance, reduced autonomy and self- 
esteem, social isolation and depression.10 This vicious 
cycle is associated with high risk of falls, increased mor-
bidity and mortality.3–6
This narrative review assesses the relationships 
between fall risk and the potential role circadian rhythms 
and melatonin play in mitigating this risk. We aim to 
provide healthcare workers adequate information about 
fall risk in older persons, including the potential role of 
the circadian rhythms and/or melatonin, as well as to lay 
foundations for future fall prevention interventional 
studies.
Search Methodology
The narrative review on the subject of “falls, circadian 
rhythms and melatonin” examined both primary and sec-
ondary sources of literature on the topic. PubMed, Web of 
Science and Google Scholar served as search engines and 
were used to access relevant literature.
Articles available on human studies in English lan-
guage, published within the last two decades, and articles 
focusing on falls, circadian rhythms and melatonin were 
included. Articles involving children or those with falls 
secondary to accidents were excluded. As the focus of this 
paper was on aging, and falls are usually associated with 
high morbidity (including longer periods of bedrest con-
finement) and mortality in older persons, special focus was 
placed on aging-related falls.
Aging, Circadian Rhythms and Falls
Aging is generally associated with weakening of the cir-
cadian system. The circadian amplitude of most physiolo-
gical variables is reduced, while the circadian phase 
becomes more labile and tends to occur earlier with advan-
cing age.11 Circadian disruption (as in shift work) is 
related to an increased risk of a host of different disease 
conditions. The elderly population faces additional envir-
onmental impact on their circadian rhythms; many drugs 
impact circadian rhythms and sleep synchronization 
(Figure 1). The chronically ill and institutionalized older 
persons as well as those in prolonged isolation, such as the 
lockdown conditions implemented during the COVID-19 
pandemic are more vulnerable to circadian dysregulation, 
mainly due to reduced exposure to natural sunlight and 
excessive exposure to artificial light at night. Even in 
healthy older people living at home, lack of daily structure 
provided by having a regular job also heightens sleep 
pattern disruption.12 Such dysregulation could in turn 
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                                     
Clinical Interventions in Aging 2020:15 2166
































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
lead to secondary disorders such as diabetes, immunosup-
pression, insomnia, depression as well as metabolic and 
cognitive disorders.13 Likewise, the presence of disease or 
a disease condition linked to the genetic makeup can also 
lead to a disturbed circadian system.
One of the most relevant circadian rhythms is the 
sleep-wake cycle, since it encompasses and orchestrates 
many other bodily rhythms. In aging, circadian rhythms 
become more fragmented, slow wave sleep (SWS) is 
reduced (which plays a key role in memory consolidation) 
and there is an increase of wakeful periods during the 
night and of inactivity intervals during the day (naps), 
which represents an age-related vulnerability to sleep dis-
orders. In turn, sleep disorders exacerbate cognitive symp-
toms in subjects with increased risk of developing 
neurodegenerative diseases, accelerating the rate of cogni-
tive decline in such patients. In addition, sleep disorders 
have been reported to exacerbate behavioral, pathophysio-
logical manifestations of dementia12 and changes in the 
circadian rhythm of activity are associated to higher risk of 
mild cognitive impairment and dementia.14
Sleep-wake cycle disruption is associated to alterations in 
the circadian rhythm of the autonomic nervous system 
(ANS) as the parasympathetic function is prevalent during 
sleep and sympathetic activity is prevalent during wake state. 
The link between aging processes and factors associated to 
an increased risk of developing autonomic dysfunction are 
well established and there is a strong association between 
heart rate variability indexes and aging.15 As there appears to 
be a relationship between cognitive status and cardiac sym-
patho-vagal balance, these factors may influence each other 
in older patients thus increasing their risk of developing 
dementia. Therefore, autonomic changes characteristic of 
normal aging could represent a vulnerability in front of the 
effects of underlying pathophysiological neurodegenerative 
processes.16
It has been suggested that circadian rhythms of ANS 
activity may play important role for maintenance of ortho-
static tolerance (OT). One way to assess OT is through the 
study of the vascular (endothelial) function as it is 
involved in vascular tone regulation and may contribute 
to the development of orthostatic intolerance. Many stu-
dies have reported a link between orthostatic hypotension 
(OH) and cognitive impairment, and suggest OH as 
a possible early marker of dementia.
Sleep disorders are among the earliest manifestations of 
many neurodegenerative diseases, even prior to cognitive 
decline due to the early affectation of brain regions respon-
sible of circadian regulation, which impact clock genes, 
body temperature, nighttime melatonin secretion and day-
time orexin secretion, as well sleep architecture (sleep frag-
mentation, sleep efficiency, rapid eye movement (REM), 
no-REM and SWS duration).12 Specifically, it has been 
shown that in Alzheimer’s disease (AD) - the main cause 
of dementia worldwide -, beta-amyloid production (AD’s 
pathophysiological hallmark) responds to a circadian 
rhythm. Thus, disrupted sleep affects both amyloid produc-
tion and clearance. Amyloid accumulation due to disrupted 
Figure 1 Aging-associated functional and cognitive decline and its relationship with autonomic function, circadian rhythms, melatonin and falls (orthostatic intolerance).
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sleep might generate a positive feedback loop, where amy-
loid accumulation would also affect sleep due to its impact 
on sleep-promoting regions.17
Sleep-wake disturbances and frailty present overlap-
ping features (systemic inflammation, cognitive impair-
ment, low physical activity, drowsiness, overactivation of 
the hypothalamic-pituitary axis (HPA), incident cardio- 
and cerebro-vascular disease, vascular and neurodegenera-
tive disorders) and predict similar outcomes. Available 
evidence suggests they most likely have a bidirectional 
relationship. Frailty reduces physical function and sociali-
zation, which affect relevant external synchronizers (social 
activities, physical exercise, outdoor sunlight exposure, 
meal scheduling) that synchronize circadian rhythms and 
promote a healthy sleep-wake cycle (Figure 1). This asso-
ciation has not been thoroughly studied yet it represents 
and interesting approach since sleep-wake disturbances are 
potentially treatable and might reverse or prevent frailty 
progression.18
In this line, the concept of “circadian reserve” is of 
increasing relevance. Similar to that of “cognitive 
reserve”, it postulates that persons with healthier circadian 
rhythmicity cope with pathological insults better than 
those with low circadian reserve. This concept posits that 
individual differences in reserves may be responsible for 
the decline, which may begin at different times in relation 
to the development of pathology. Many of the aspects 
involved in this “circadian reserve” can be promoted in 
the aging population to foster a healthier lifestyle and 
quality of life.
Falls perhaps contribute most to the decline in the 
quality of life of older persons. It has been reported that 
being prone to falling is one of the strongest predictors of 
nursing home placement.19 Falls and their resulting inju-
ries are responsible for major health, social, and economic 
problems. A systematic review of the literature concluded 
that the incidence of falls in older persons follows 
a circadian variation.20 A better understanding of condi-
tions in which falls occur can lead to the implementation 
of countermeasures (such as adjusting the scheduling of 
hospital staff, or changing the timing of anti-hypertensive 
medication if falls are related to undesirable circadian 
patterns of blood pressure and/or heart rate). This includes 
knowing the times of the day, days of the week, and times 
of the year when falls are more likely to occur at home or 
in the hospital. The systematic recording of such events, 
and circumstances in which they occur, will be amenable 
to chronobiological analyses. A suite of computer 
programs for the assessment and comparison of rhythmic 
patterns has been developed at the Halberg Chronobiology 
Center, and has been made freely available online.21 
Whether for prevention or as an adjuvant modality of 
care, strengthening the circadian system thus presents 
itself as a novel and promising strategy to examine falls 
in older persons.
Chronobiological Interventions
Falls were found to be more frequent on Fridays, Sundays, 
and Mondays compared with Tuesdays, and were more 
frequent in winter and spring.20 Circadian rhythms are 
genetically anchored. Their endogenous period differs 
only slightly, but statistically significantly, from exactly 
24 hours. External synchronizers are important to keep 
circadian rhythms in sync. Strengthening the circadian 
system can thus be accomplished by enhancing external 
synchronizers.
The alternation between light and darkness, and 
between activity and rest/sleep, is of primary importance 
since the lighting regimen acts directly on the suprachias-
matic nuclei, thought to orchestrate the entire circadian 
system. Because light is sensed via the eyes and the 
optic nerve, preventing conditions such as glaucoma is 
important.22 Exposure to sun light during the day, notably 
in the morning, and turning lights off during the night is 
highly recommended.
The feeding schedule is also important since it syn-
chronizes circadian clock genes in peripheral organs such 
as the liver. Circadian clocks are also tightly coupled to 
cellular metabolism. As a consequence, time-restricted 
feeding and other meal scheduling plans are currently 
been tested for their effect on geroprotection. In the 
experimental laboratory, time-restricted feeding has been 
shown to increase the circadian amplitude of important 
physiological variables, an indication of an enhanced cir-
cadian system. Caloric restriction, often associated with 
time-restricted feeding, has long been known to be asso-
ciated with prolonged longevity.23 Regular exercise is 
another non-pharmacologic intervention known to be ben-
eficial to health and to support a strong circadian system. 
The beneficial effects of exercise are well known in rela-
tion to rehabilitation, for instance.
The development of geroprotectors is an active field of 
research. For instance, the use of metformin has attracted 
much interest, also beyond its administration to 
patients with non-insulin-dependent diabetes mellitus. 
Molecular pathways underlying effects of metformin 
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show cross-talk with circadian clock genes. Melatonin (see 
below) is another molecule, which has shown beneficial 
effects in relation to a number of disease conditions. One 
of its beneficial effects may be its action in increasing 
sleep quality, again related to the strengthening of the 
circadian system.
The longitudinal monitoring of physiological variables 
has been advocated as a means of health surveillance, 
notably when the data are interpreted chronobiologically. 
Indeed, the quantitative assessment of rhythmic behavior 
amounts to entering inside the physiological range, where 
deviations from norms can prompt the timely institution of 
prophylactic intervention aiming at primary prevention.11 
An example of this approach relates to the ambulatory 
monitoring of blood pressure (ABPM). In the BIOCOS 
project, ABPM records were collected in clinically healthy 
individuals from the first few days of life to centenarians, 
and also during pregnancy. On their basis, time-specified 
reference values and reference standards for the circadian 
parameters were built for males and females in different 
age groups.24 These chronobiologic norms are now used to 
assess the health status of volunteers and patients who 
typically undergo a 7-day/24-hour ABPM session. The 
analysis of their data can determine whether their circadian 
variation in blood pressure and heart rate is within accep-
table limits or whether it deviates from norms. In such 
a case, the diagnosis goes beyond the detection of a mere 
elevated blood pressure, since the circadian amplitude and/ 
or phase can also be abnormal. Several outcome studies 
have shown that such abnormal behavior of the circadian 
amplitude and/or phase is also associated with an 
increased cardiovascular disease risk, and that this risk 
can be higher than the risk associated with an elevated 
blood pressure alone.25 Some indirect evidence also exists 
showing that the restoration of a healthy circadian profile 
of blood pressure can reduce the incidence of strokes and 
that of overall cardiovascular mortality.26
A chronobiologic approach can thus save lives. It can 
also save costs, as suggested by a few case studies. One 
notorious case is that of a pregnant woman who had an 
excessive circadian amplitude of her blood pressure pro-
file. Since this observation was made at the beginning of 
a new research study, the obstetrician took no special 
action since the average blood pressure was well within 
acceptable limits. Eight weeks later, however, this preg-
nant woman delivered prematurely, and her infant boy had 
to be hospitalized for most of the first two years of his life. 
Cost-accounted medical costs related to the first year of 
care amounted to over 1 million dollars.27
Evaluation of the autonomic nervous system as a tool 
for detecting the risk of falling is becoming increasingly 
relevant and is being actively researched.28–32 Different 
studies have used ANS evaluation and, in particular, 
heart rate variability (HRV) to detect and predict the risk 
of falling in various populations.19,33 The identification of 
autonomic parameters as markers of risk of falling will 
help detect and monitor subjects prone to falling early on 
as well as allow for the implementation of preventive 
strategies.34,35 There is no literature on the study of the 
circadian rhythm of the ANS, yet given the existing 
research on the subject and the fact that HRV is a fast, non- 
invasive, affordable and easily implemented technique, 
a 24hr HRV assessment presents and attractive and pro-
mising approach to the study of frailty and falls in older 
persons.
Longitudinal monitoring of physical and cognitive 
functions can be helpful in detecting early signs of frailty. 
A battery of tests can assess physical and cognitive func-
tion in older persons. In a Japanese community, central 
blood pressure was found to be a long-term predictor of 
cognitive decline in older adults, whereas preserved phy-
sical activity was found to be a short-term predictor of 
cognitive improvement.36 Any changes in cognitive func-
tion may be accompanied by changes in sleep character-
istics. Intervening early may hence mitigate the 
development of insomnia-related diseases.
Whether one is concerned with disease prediction and 
prevention or maintenance of healthy aging, the study of 
circadian rhythms and the broader time structure under-
lying physiopathology is helpful in terms of screening, 
early diagnosis and prognosis, as well as the timely insti-
tution of prophylactic and/or palliative/curative treatment. 
Timing the administration of such treatment as a function 
of circadian (and other) rhythms also brings considerable 
benefits. Indeed, chronotherapy (timed treatment) can 
make the difference between life and death in the experi-
mental laboratory and between health and disease in 
humans.37
Melatonin and Falls: A Possible 
Relationship?
Melatonin can be assessed in blood, saliva and urine. 
A prominent circadian rhythm characterizes melatonin, 
which peaks during the night in both diurnal and nocturnal 
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mammals. Interestingly, melatonin also undergoes about- 
weekly (circaseptan) and about-yearly (circannual) 
variations.24,38,39 While most investigators focus on noc-
turnal melatonin, the circadian characteristics of melatonin 
can also be informative. The circadian amplitude of mel-
atonin differs both in terms of breast cancer risk40 and the 
presence of overt cancer.41 Some genetic mutations are 
also associated with a shift in the circadian phase of 
melatonin.27
The circadian amplitude of melatonin decreases as 
a function of age,11 raising the questions whether such 
a decrease in the circadian amplitude of melatonin relates 
to a higher risk of falls (Figure 1) and, if so, whether mela-
tonin supplementation may be an effective countermeasure. 
Indeed, a direct link between sleep quality, falls risk and 
melatonin has been shown. For instance, sleep disturbances – 
independent of confounders – have been shown to be asso-
ciated with increased risk of falls in older men.42 By improv-
ing sleep in older persons, melatonin could play an important 
role in falls prevention in older persons.
As a chronobiotic/cytoprotective agent, melatonin 
occupies a special place in the prevention and treatment 
of age-related disorders.43 Melatonin improves sleep effi-
ciency and has antioxidant and anti-inflammatory proper-
ties, in part because of its function as a metabolic regulator 
and mitochondrial protector.44–46 Melatonin, an unusually 
phylogenetic conserved molecule present in all known 
aerobic organisms, is effective both as a chronobiotic and 
as a cytoprotective agent.
The light-dark variation in the synthesis of melatonin 
by pinealocytes is the essential fact that explains the role 
of melatonin as a chronobiotic that coordinates the phy-
siology of biological rhythms.47 The action of melatonin 
as a chronobiotic is twofold: on the one hand, it “opens the 
doors of sleep” by inhibiting the promoting activity of late 
awakening driven by suprachiasmatic nuclei (SCN).48,49 
On the other hand, melatonin is the “hormone of dark-
ness”, a chemical code of the duration of the night, and 
has established itself as crucial in the transmission of 
information from light to the neuroendocrine system. 
Melatonin represents a “hand” of the biological clock in 
the sense that it responds to the signals of the SCN, the 
temporal variation of the melatonin rhythm indicating 
the state of the clock, both in terms of phase (time in the 
internal clock in relation to external time) and 
amplitude.50
In mammals, circulating melatonin is derived almost 
exclusively from the pineal gland. In addition, melatonin is 
synthesized locally in many cells, tissues and organs. 
Indeed, there is now strong evidence that melatonin is 
produced in every animal cell that has mitochondria.51 In 
both animals and humans, melatonin participates in 
diverse physiological functions that indicate not only the 
duration of the night, but also improve the elimination of 
free radicals and the immune response, showing relevant 
neuroprotective properties.52
The chronobiotic action of melatonin is mediated via 
the melatonin (MT) receptors, which have been identified 
both in the central nervous system (CNS) and in the 
periphery.53 MT1 and MT2 receptors all belonging to the 
superfamily of membrane receptors associated with 
G proteins (G-protein coupled receptors, GPCR) have 
been cloned. More recently, another member, GPR50, 
was included in the melatonin receptor subfamily. 
GPR50 shows high sequence homology to MT1 and 
MT2 but does not bind to melatonin or any other known 
ligand. An interesting feature of these receptors is their 
capacity to form homo- and heteromers between each 
other and also with other GPCRs.54
The cytoprotective activity of melatonin exceeds that 
mediated via receptors. Almost every cell in the human 
body contains melatonin, in quantities much higher than 
those circulating in blood derived from the pineal gland.55 
The mitochondrial capacity to synthesize melatonin is now 
confirmed, but for reasons that remain unexplained, intra-
cellular melatonin does not get the extracellular space. To 
modify intracellular melatonin levels, doses much higher 
than those employed as a chronobiotic are needed.56 Most 
studies on neuroprotective and anti-inflammatory effects in 
animals employ pharmacological doses, which clearly 
exceed the saturation of the receptor.
Concerning falls and frailty, several aspects of melatonin 
action must be considered. In a study designed to identify the 
role of melatonin in cerebellum balance disturbances and 
cognitive disorders, spatial memory was highly altered in 
subjects with inversion of circadian melatonin rhythm, an 
indication of circadian disruption.57 This possible negative 
correlation among melatonin, the cerebellum and human 
balance was suggested by a double-blind pilot study in 
which 10 mg of melatonin was administered to 14 healthy 
volunteers at 10.00 a.m. to reproduce the abnormally high 
diurnal values of the pineal methoxyindole.58 Since melato-
nin is often used as a sleeping aid in older adults, it was 
important to determine whether treatment does not cause any 
hangover effect that could potentially lead to falls and frac-
tures. In a double-blind placebo-controlled study, 81 
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postmenopausal women with osteopenia received 1 or 3 mg 
melatonin, or placebo nightly for 12 months.59 Postural bal-
ance as well as muscle function was measured. Compared to 
placebo, one-year treatment with melatonin did not affect 
postural balance or risk of falls nor modified muscle strength.
A number of studies point out to a preventive role of 
melatonin in sarcopenia.60,61 For example, in postmeno-
pausal women low levels of 6-sulfatoxymelatonin excre-
tion correlated with sarcopenia.62 Moreover, enhanced 
urinary melatonin metabolite was associated with more 
grip and quadriceps muscle strength in aged persons.63 
However, in previously sedentary men and women aged 
40–75 years after one year of moderate exercise, the 
urinary melatonin metabolite levels were unchanged.64
Sarcopenia is characterized by the occurrence of insu-
lin-resistance65 and exogenous melatonin decreases insulin 
resistance, ameliorates mitochondrial function and pre-
vented chemically induced apoptosis and endoplasmic 
reticulum stress in skeletal muscle cells in vivo and in -
vitro.61 Therefore, exogenous melatonin can be useful as 
an antioxidant and an anti-inflammatory agent the prolong 
muscle strength and adaptation during exercise in adult-
hood and aging. For example, in a study examining 
a possibly beneficial effect of a 1year-long administration 
of melatonin (3 mg/day) on body composition and lipid 
metabolism increases in lean mass and decreases in fat 
mass were observed.66
Accumulating evidence has also indicated that melato-
nin may be involved in the homeostasis of bone metabo-
lism. Age-related reductions in melatonin are considered 
to be critical factors in bone loss and osteoporosis with 
aging, and serum melatonin levels may serve as 
a biomarker for the early detection and prevention of 
osteoporosis.67 In comparison to conventional antiosteo-
porotic agents, which primarily inhibit bone loss, melato-
nin both suppresses bone loss and promotes new bone 
formation. By activating melatonin receptor 2, melatonin 
upregulates the gene expression of alkaline phosphatase, 
bone morphogenetic protein 2 (BMP2), BMP6, osteocal-
cin, and osteoprotegerin to promote osteogenesis while 
inhibiting the receptor activator of NF-kB ligand pathway 
to suppress osteolysis.67 In humans, bone mineral density 
in the femoral neck of postmenopausal osteopenic women 
increased in response to melatonin in a dose-dependent 
manner when compared with a placebo.68 Likewise, in 
a one-year double blind randomized control trial assessing 
the effects of nightly melatonin, strontium (citrate), vita-
min D3 and vitamin K2 on bone mineral density in 
postmenopausal osteopenic women treatment increased it 
in lumbar spine and left femoral neck.69
Melatonin exhibits both hypnotic and chronobiotic 
properties and has been used therapeutically for the treat-
ment of insomnia related to age, as well as other primary 
and secondary insomnia. Several meta-analyses support 
this role.70–72 A consensus of the British Association of 
Psychopharmacology on the evidence-based treatment of 
insomnia, parasomnia and sleep disorders in the circadian 
rhythm concluded that melatonin is the first-choice treat-
ment when a hypnotic is indicated in patients older than 55 
years.73 A similar conclusion was reached by a recent 
consensus of five Italian Medical Societies74 as well as 
by the expert recommendations from the French institute 
of medical research on sleep concerning melatonin use in 
adult psychiatric disorders.75
As discussed recently,56 studies using 2–5 mg of mel-
atonin/day are not adequate to provide an adequate com-
parison with data on the protection in metabolic syndrome 
or neurodegenerative disorders derived from animal stu-
dies. Hence, clinical trials with doses in the 40–100 mg/ 
day range are urgently needed. It should be noted, how-
ever, that purpose for melatonin administration must be 
considered for its optimal dosing and timing: while such 
high doses for receptor-independent antioxidant effects are 
warranted,76 high doses may desensitize specific melatonin 
receptors77 thereby preventing its pro-circadian78 and 
other receptor-mediated effects. For example, lack of 
hypotensive effect could occur due to too high doses 
(24mg) of administered melatonin.79
It should be noted that melatonin is remarkably non- 
toxic, and its safety is very high. In humans, melatonin has 
a high safety profile and, in general, is very well tolerated.
Vagal Tone and Fall Risk
An additional factor influencing the fall risk in older 
persons might be the decrease of vagal activity with age 
(Figure 1). Although vagal tone over-all diminishes arter-
ial blood pressure important for a good blood supply to the 
brain, the decrease of vagal activity also reduces the ability 
to regulate blood pressure fast, which might be more 
important for position control than a high blood pressure.
Vagal neurons, utilizing acetylcholine in their final 
synapses, allow a faster control of heart rate than their 
sympathetic sisters.80 Vagal acetylcholine is cleared by 
a fast chemical decay mediated by cholinesterase, whereas 
the sympathetic norepinephrine depend on a clearing of 
the synapses by pre-synaptic re-uptake of the transmitter 
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molecules after excitation. It is known that respiratory 
oscillations of heart rate counter-regulate the oscillations 
of carotid blood pressure due to respiratory movements 
and intrathoracic pressure changes.81 Up to the intrinsic 
heart rate of about 110 b/min, most of the blood regulation 
is carried out via the vagus nerve.
During aging, vagal activity and vagal oscillations of 
heart beat dynamic reduce,82 only in some individuals, 
usually the almost centenarians, this is not the case.83 Until 
the early 70th there is a continuous decline, whereas elder 
people display no more reduction of vagal tone.83 Acutely 
administered melatonin stimulates vagal activity and reduces 
the heart rate.84 It may therefore be used to support the 
reduction of blood pressure in hypertensives, likely by this 
activation of vagal tone, and might be helpful to support fast 
blood pressure regulation due to vagal enhancement. To our 
knowledge this aspect has not yet been fully investigated. 
Only one study has investigated the effectiveness of mela-
tonin in regulation of BP specifically in the older population. 
In this randomized trial carried out in adults between 63 −91 
years, the hypotensive effect of melatonin was most pro-
nounced between 3:00 and 8:00 in the morning, pointing at 
timing of its pronounced effect during hours corresponding 
to greatest cardiovascular risks.85
Conclusions and Future Directions
Whether one is concerned with disease prediction and preven-
tion or maintenance of healthy aging, the study of circadian 
rhythms and the broader time structure underlying physio-
pathology is helpful in terms of screening, early diagnosis 
and prognosis, as well as the timely institution of prophylactic 
and/or palliative/curative treatment. Timing the administration 
of such treatment as a function of circadian (and other) 
rhythms also could lead to reduction of falls in older persons.
There is no literature on the study of the circadian 
rhythm of the ANS, yet given the existing research on 
the subject and the fact that HRV is a fast, non-invasive, 
affordable and easily implemented technique, a 24hr HRV 
assessment presents an attractive and promising approach 
to the study of frailty and falls in older persons.
Finally, a prominent circadian rhythm characterizes 
melatonin, which peaks during the night. The circadian 
amplitude of melatonin decreases as a function of age, 
raising the questions whether such a decrease in the circa-
dian amplitude of melatonin relates to a higher risk of falls 
and, if so, whether melatonin supplementation may be an 
effective countermeasure.
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